Melatonin in chagas disease : possible therapeutic value

Mostrar todas las versiones(2)

Abstract: Chagas’ disease is a severe health problem in Latin America, causing approximately 50 000 deaths a year, with approximately 18 million infected people. About 25-30% of the patients infected with Trypanosoma cruzi develop the chronic form of the disease. The protective response against T. c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cardinali, Daniel Pedro, Álvarez, Carlos B.
Formato: Artículo
Lenguaje:Inglés
Inglés
Publicado: Fundación Revista Medicina 2019
Materias:
MELATONINA
ENFERMEDAD DE CHAGAS
RECEPTORES DE MELATONINA
ESTRES OXIDATIVO
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/1663
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139123456789-1663
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
Inglés
topic MELATONINA
ENFERMEDAD DE CHAGAS
RECEPTORES DE MELATONINA
ESTRES OXIDATIVO
spellingShingle MELATONINA
ENFERMEDAD DE CHAGAS
RECEPTORES DE MELATONINA
ESTRES OXIDATIVO
Cardinali, Daniel Pedro
Álvarez, Carlos B.
Melatonin in chagas disease : possible therapeutic value
topic_facet MELATONINA
ENFERMEDAD DE CHAGAS
RECEPTORES DE MELATONINA
ESTRES OXIDATIVO
description Abstract: Chagas’ disease is a severe health problem in Latin America, causing approximately 50 000 deaths a year, with approximately 18 million infected people. About 25-30% of the patients infected with Trypanosoma cruzi develop the chronic form of the disease. The protective response against T. cruzi depends on both innate and acquired immunity involving macrophages, natural killer cells, T and B lymphocytes, and the production of proinflammatory Th-1 cytokines. In addition, an increased nitric oxide (NO) production in macrophages leading to effective microbicidal action is needed to control parasitemia. Melatonin is detectable in T. cruzi and may play a role in promoting infection whereas, when administered in high doses during the acute phase of T. cruzi infection, it can decrease parasitemia while reducing NO production. During chronic disease progression, the sustained oxidative stress concomitant to myocardial damage could be reduced by administering melatonin. It is hypothesized that the coordinated administration of a melatonin agonist like the MT1/MT2 agonist ramelteon, that lacks antioxidant activity and may not affect NO production during the acute phase, and of melatonin in doses high enough to decrease oxidative damage, to preserve mitochondrial and to prevent cardiomyopathy during the chronic phase, could be a novel add-on treatment of Chagas´ disease.
format Artículo
author Cardinali, Daniel Pedro
Álvarez, Carlos B.
author_facet Cardinali, Daniel Pedro
Álvarez, Carlos B.
author_sort Cardinali, Daniel Pedro
title Melatonin in chagas disease : possible therapeutic value
title_short Melatonin in chagas disease : possible therapeutic value
title_full Melatonin in chagas disease : possible therapeutic value
title_fullStr Melatonin in chagas disease : possible therapeutic value
title_full_unstemmed Melatonin in chagas disease : possible therapeutic value
title_sort melatonin in chagas disease : possible therapeutic value
publisher Fundación Revista Medicina
publishDate 2019
url https://repositorio.uca.edu.ar/handle/123456789/1663
work_keys_str_mv AT cardinalidanielpedro melatonininchagasdiseasepossibletherapeuticvalue
AT alvarezcarlosb melatonininchagasdiseasepossibletherapeuticvalue
bdutipo_str Repositorios
_version_ 1764820525793673218

Ejemplares similares